论文部分内容阅读
目的高效抗反转录病毒治疗(HAART)后免疫重建不良的艾滋病(AIDS)病人,更换用克力芝(LPV/r)后,对于免疫功能特别是CD+4T淋巴细胞(CD4细胞)计数的改善作用。方法观察66例因HAART后免疫重建不良而改用克力芝的AIDS病人,与继续原方案治疗的病人1年后的CD4细胞计数,对比研究两组病人治疗前、免疫重建不良时和换药1年后的CD4细胞计数。结果克力芝组30例病人,免疫重建不良时的CD4细胞计数与抗病毒治疗前基线CD4细胞计数比较,差异无统计学意义(P>0.05)。换药1年后,CD4细胞计数较基线和免疫重建不良时均有明显升高,差异有统计学意义(P<0.05);对照组36例病人基线时、免疫重建不良时及继续治疗1年后的CD4细胞计数,经组间两两比较差异无统计学意义(P>0.05)。结论换用克力芝可改善HAART后免疫功能重建不良的情况,继续使用两种核苷类反转录酶抑制剂加一种非核苷类反转录酶抑制剂方法不能改善免疫重建不良的情况。
Objective To count the immune function, especially CD + 4T lymphocytes (CD4 cells), after immunocompromised AIDS patients after highly active antiretroviral therapy (HAART) Improve effect Methods Sixty-four AIDS patients who switched to Kelixe because of poor immune reconstitution after HAART were compared with CD4 cell counts one year after they were treated with the original regimen. The comparison of the two groups before treatment, poor immune reconstitution and dressing change CD4 cell count after 1 year. Results There was no significant difference in the count of CD4 cells between the glioso group and the baseline CD4 cell count before anti-virus therapy in 30 patients with poor immune reconstitution (P> 0.05). One year after the dressing change, the CD4 cell count was significantly higher than that of the baseline and immune reconstitution (P <0.05), while in the control group, the baseline time of 36 patients with poor immune reconstitution and the continued treatment for one year After the CD4 cell count, no significant difference between groups by comparison (P> 0.05). CONCLUSION: The exchange of Keribizumab can improve the immune reconstruction dysfunction after HAART. The continuous use of two nucleoside reverse transcriptase inhibitors plus one non-nucleoside reverse transcriptase inhibitor can not improve the immune reconstitution .